Thiamine Intervention and Coronary Artery Bypass Grafting
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Mar 20, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how brain changes and thinking difficulties after heart surgery (specifically coronary artery bypass grafting, or CABG) are connected in patients with coronary heart disease (CHD). The researchers want to see if giving a low-cost vitamin called thiamine can help reduce these cognitive problems after surgery. The study is currently recruiting patients aged 21 to 92 who have CHD and are scheduled for CABG, particularly those who are known to have low thiamine levels.
To take part in the trial, participants should not have severe dementia or be currently taking thiamine, and they should meet certain health criteria. If eligible, participants will receive thiamine before their surgery and be monitored for any changes in their thinking skills afterward. It's a chance to contribute to important research that could potentially help many patients improve their recovery after heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)
- • Thiamine deficiency before CABG
- • European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \>1.5%
- • Off-pump surgery
- Exclusion Criteria:
- • Dementia at baseline \[Montreal Cognitive Assessment (MoCA) \<21 within 5 days before CABG\]
- • Current in-take of thiamine
- • Known thiamine allergy
- • Uncontrolled blood glucose levels
- • Unable to give consent due to illness
- • History of hyperlactatemia
- • Recent (within several years and/or up to the judgment of the PI/co-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and/or concussion)
- • Stroke
- • Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)
- • Patients with history of alcohol or substance abuse
- • Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)
- • Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)
- • Chronic immunodeficiency (including HIV)
- • Congenital brain deficits will also be excluded
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Rajesh Kumar, PhD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported